Literature DB >> 32235771

BoLA-DRB3 Polymorphism is Associated with Differential Susceptibility to Bovine Leukemia Virus-Induced Lymphoma and Proviral Load.

Chieh-Wen Lo1,2,3, Liushiqi Borjigin2,4, Susumu Saito2,3,5, Koya Fukunaga6, Etsuko Saitou7, Katsunori Okazaki8, Tetsuya Mizutani5, Satoshi Wada3, Shin-Nosuke Takeshima2,3,9, Yoko Aida1,2,4,5.   

Abstract

Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leucosis. However, less than 5% of BLV-infected cattle will develop lymphoma, suggesting that, in addition to viral infection, host genetic polymorphisms might play a role in disease susceptibility. Bovine leukocyte antigen (BoLA)-DRB3 is a highly polymorphic gene associated with BLV proviral load (PVL) susceptibility. Due to the fact that PVL is positively associated with disease progression, it is believed that controlling PVL can prevent lymphoma development. Thus, many studies have focused on the relationship between PVL and BoLA-DRB3. Despite this, there is little information regarding the relationship between lymphoma and BoLA-DRB3. Furthermore, whether or not PVL-associated BoLA-DRB3 is linked to lymphoma-associated BoLA-DRB3 has not been clarified. Here, we investigated whether or not lymphoma-associated BoLA-DRB3 is correlated with PVL-associated BoLA-DRB3. We demonstrate that two BoLA-DRB3 alleles were specifically associated with lymphoma resistance (*010:01 and *011:01), but no lymphoma-specific susceptibility alleles were found; furthermore, two other alleles, *002:01 and *012:01, were associated with PVL resistance and susceptibility, respectively. In contrast, lymphoma and PVL shared two resistance-associated (DRB3*014:01:01 and *009:02) BoLA-DRB3 alleles. Interestingly, we found that PVL associated alleles, but not lymphoma associated alleles, are related with the anti-BLV gp51 antibody production level in cows. Overall, our study is the first to demonstrate that the BoLA-DRB3 polymorphism confers differential susceptibility to BLV-induced lymphoma and PVL.

Entities:  

Keywords:  BoLA-DRB3; association study; bovine leukemia virus; lymphoma; polymorphism; proviral load; resistance; susceptibility

Mesh:

Substances:

Year:  2020        PMID: 32235771      PMCID: PMC7150773          DOI: 10.3390/v12030352

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


1. Introduction

Viral load in chronic infections with viruses, such as hepatitis B virus (HBV), hepatitis C virus (HCV), human T cell leukemia virus type 1 (HTLV-1), and human immunodeficiency virus type 1 (HIV-1), has been reported to determine the likelihood of pathogenesis and disease progression [1,2,3,4]. For retroviruses, whose genome integrates with the host genome, proviral load (PVL) is an important risk factor of viruss-associated disease prediction [5,6]. Bovine leukemia virus (BLV) is closely related to HTLV-1 and is the causative agent of enzootic bovine leukosis (EBL), a disease that is characterized by long-term symptoms, including persistent lymphocytosis (PL), which may culminate in B-cell lymphosarcoma [7,8]. Several studies indicate that BLV PVL is associated with BLV-related disease progression [9,10,11,12,13]. However, only 5% of infected cattle progress to develop lymphoma, suggesting that in addition to viral infection, host genetic polymorphisms might play a role in disease susceptibility. The major histocompatibility complex (MHC), a highly polymorphic gene set, plays a crucial role in antigen presentation and immune responsiveness [14,15,16], and thus, it is associated with numerous infectious diseases. In cattle, the MHC system is known as bovine leukocyte antigen (BoLA). Several studies have identified genetic variations in BoLA-DRB3, a functionally important locus and the most highly polymorphic BoLA class II locus in cattle. To date, 330 DRB3 alleles have been registered in the Immuno Polymorphism Database (IPD)- MHC database (https://www.ebi.ac.uk/ipd/mhc/group/BoLA/). The BoLA-DRB3 polymorphism influences susceptibility to BLV-induced lymphoma [17,18,19], and to PVL [20,21,22]. As PVL is positively related to lymphoma development, it is possible that lymphoma-associated BoLA-DRB3 is consistent with PVL-associated BoLA-DRB3. However, the consistency of the above association has not been studied yet. Indeed, lymphoma development and viral replication depend on different cellular mechanisms, potentially leading to the differential susceptibility of lymphoma and PVL to BoLA-DRB3. It has been reported that proviral integration and BLV proteins are required for initial cell transformation [7,23]. However, the host immune system can remove transformed cells by lymphocyte activation via MHC molecules [24]. Due to the fact that MHC class II alleles affect antigen presentation and MHC expression levels in cancer cells [25,26], it is reasonable to hypothesize that MHC class II alleles would bind to peptides derived from viral or tumor antigens, and that the resulting complex would be recognized by CD4+ T cells. Consequently, some BoLA-DRB3 alleles might specifically bind with the processed viral antigen, while others might specifically recognize the tumor antigens. Thus, it is likely that different BoLA-DRB3 alleles are specifically associated with BLV-induced lymphoma and PVL. Consistent with this, PVL does not always correlate with lymphoma development, as many infected cows with a high PVL do not develop lymphoma. On the contrary, attenuated BLV-infected sheep were found to exhibit significantly lower PVL, but still developed lymphoma [27], suggesting that lymphoma and PVL may induce different susceptibilities, depending on different BoLA-DRB3 polymorphisms. In this study, using asymptomatic and lymphoma Holstein cows randomly collected in a nationwide survey in Japan, we demonstrated that BoLA-DRB3 polymorphism is associated with differential susceptibility to BLV-induced lymphoma and PVL.

2. Materials and Methods

2.1. Sample Collection and Diagnosis

Blood samples from 611 BLV-infected but clinically normal Holstein cows (asymptomatic cows; information summarized in Tables S1 and S6) and 221 BLV-infected Holstein cows with lymphoma (lymphoma cows; information summarized in Table S2) were randomly collected in a nationwide survey across Japan (32 prefectures out of 47), and the genomic DNA and plasma from peripheral blood were isolated. The subclinical stage of BLV infection was diagnosed according to the lymphocyte count (cells/μL) and the age of each cow (≤ 8,500 = normal and ≥ 13,000 = lymphocytosis for cows aged 2–3 years; ≤ 5,500 = normal and ≥ 7,500 = lymphocytosis for cows aged ≥ 6 years). Asymptomatic cows were defined as BLV-infected but clinically and hematologically normal cattle; PL cows were defined as BLV-infected but clinically normal cattle showing with an increase in the number of apparently normal B lymphocytes. Subsequently, lymphoma was diagnosed by both gross and histological observation and by detecting atypical mononuclear cells in the slaughterhouse. In this study, PL cases were excluded and used only samples from asymptomatic cows and lymphoma cows.

2.2. BLV Proviral Load Determination

BLV infection was estimated by BLV-CoCoMo-qPCR-2 (RIKEN Genesis, Kanagawa, Japan), as previously described [9,10,28,29,30]. Briefly, the BLV-LTR region was amplified in a reaction mixture containing THUNDERBIRD Probe qPCR Mix (Toyobo, Tokyo, Japan), CoCoMo FRW primer, CoCoMo REV primer, FAM-BLV probe, and 150 ng of template DNA. In addition, the BoLA-DRA region was amplified as internal control. The proviral load was calculated using the following equation: (number of BLV-LTR copies /number of BoLA-DRA copies) × 105 cells.

2.3. BoLA-DRB3 Genotyping

BoLA-DRB3 alleles were determined using the PCR-sequenced-based typing (SBT) method, as previously described [31]. Briefly, BoLA-DRB3 exon 2 was amplified by single-step PCR using the DRB3 forward (5’-CGCTCCTGTGAYCAGATCTATCC-3’) and DRB3 reverse (5’-CACCCCCGCGCTCACC-3’) primer set. The PCR products were purified by the ExoSAP-IT PCR product purification kit (USB Corp., Cleveland, OH, USA), and then sequenced using the ABI PRISM BigDye1.1 Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA). The sequence data were then analyzed using Assign 400ATF ver. 1.0.2.41 software (Gonexio Genomics, Fremantle, Australia) to determine the BoLA-DRB3 genotype.

2.4. Detection of Anti-BLV gp51 Antibody by Enzyme-Linked Immunosorbent Assay (ELISA)

The anti-BLV gp51 antibody was measured with an anti-BLV antibody ELISA Kit (JNC, Tokyo, Japan), according to the manufacturer’s instructions. Two-fold serial dilutions of plasma samples starting at 1:16 were tested by the ELISA Kit. The OD value in each DRB3 group was compared at each dilution.

2.5. Association Study and Statistical Analysis

An association study based on Fisher’s exact test was performed by comparing the allele and genotype frequencies between asymptomatic and lymphoma cows or low PVL and high PVL cows. The results were penalized with the Benjamini–Hochberg (BH) procedure to correct for the false positive rate. Each allele or genotype was ranked based on their p-value starting from the smallest one. The BH value was calculated based on the equation p-value rank / total allele (genotype) number × 0.05). The alleles or genotypes with p-value < BH value and odds ratio (OR) < 1 were categorized as resistance alleles. In contrast, those with p-value < BH value and OR > 1 were defined as susceptibility alleles or genotypes. The association of cow mean age and birth location with lymphoma or PVL was evaluated by the Mann–Whitney U test and Tukey’s multiple comparison test, respectively. When we confirmed the association between age and lymphoma or PVL, we performed logistic regression analyses to adjust for age. To evaluate a multiplicative interaction between BoLA-DRB3 alleles, we introduced the interaction term in a logistic regression model as conditional analysis [32]. We assessed the significance level of the association study by applying a Bonferroni correction according to the number of assessed alleles (adjusted p < 0.05). All calculations were performed using R software (version 3.5.0, R Foundation for Statistical Computing, Vienna, Austria).

3. Results

3.1. PVL Is Not Fully Correlated with Lymphoma Development

The PVL of 250 asymptomatic cows (Table S1) ranged from 5–120,482 copies/105 cells (mean: 9401 copies/105 cells), while in 221 lymphoma cows (Table S2), the PVL ranged from 28–1,960,674 copies/105 cells (mean 99,522 copies/105 cells; Figure 1). This difference suggested that animals with a high BLV PVL were at a higher risk of developing lymphoma. Our previous report indicated that cows with a PVL of greater than 14,000 copies/105 cells secreted BLV into nasal mucus [30], and BLV provirus was detected in milk samples from cows when the PVL in blood samples was higher than 10,000 copies/105 cells [33]. These results suggest that a PVL around 10,000 copies/105 cells in blood might be an indicator of efficient BLV spreading within the whole body and thus this is a relatively high number. Therefore, a BLV PVL of 10,000 copies/105 cells was set as a threshold to distinguish between high-PVL (HPVL) and low-PVL (LPVL) cows (Figure 1), which is also in line with our previous study [19]. Consistently, in lymphoma and asymptomatic cows, the mean PVL was found to be above and below this threshold, respectively (Figure 1). However, 62 HPVL cows remained asymptomatic, whereas 37 LPVL cows developed lymphoma (Table 1), indicating that lymphoma development is not fully correlated with the PVL. This could be because BLV-induced lymphoma and BLV PVLs are associated with different BoLA-DRB3 alleles.
Figure 1

Proviral load (PVL) estimation in Bovine leukemia virus (BLV)-infected but clinically and hematologically normal cows (asymptomatic cows) and BLV-infected cows with lymphoma (lymphoma cows). Blood samples were obtained from 250 asymptomatic (Table S1) and 221 lymphoma (Table S2) cows in a nationwide survey in Japan. BLV infection was analyzed using BLV-CoCoMo-qPCR-2. The red line represents a BLV PVL of 10,000 copies/105 cell, which was set as the threshold between high- and low-PVL cows.

Table 1

Summary of PVL distribution in asymptomatic cows and lymphoma cows.

StatusAsymptomatic (n = 250)Lymphoma (n = 221)
Low proviral load 118837
High proviral load 262184

1 A PVL of < 104 copies/105 cells was considered Low proviral load; 2 a PVL of > 104 copies/105 cells was considered High proviral load.

3.2. Association Study of BoLA-DRB3 with Lymphoma

Next, to explore the association between BoLA-DRB3 and lymphoma, all 250 asymptomatic and 221 lymphoma cows were typed for BoLA-DRB3 alleles (Table S3). The alleles with frequencies > 1% are shown in Figure 2. An association study based on Fisher’s exact test found that DRB3*009:02 (OR = 0.23), DRB3*010:01 (OR = 0.48), DRB3*011:01 (OR = 0.56), and DRB3*014:01:01 (OR = 0.57) were classified as lymphoma resistance alleles, whereas DRB3*012:01 (OR = 2.71) and DRB3*015:01 (OR = 1.67) were identified as lymphoma susceptibility alleles (Table 2).
Figure 2

Comparison of BoLA-DRB3 allele frequencies between asymptomatic and lymphoma cows. Allele frequency in 250 asymptomatic (■) and 221 lymphoma (□) cows were calculated for each BoLA-DRB3 allele (Table S3); 13 out of 32 alleles with frequency > 1% are shown. The X-axis shows the allele name and the Y-axis shows allele frequency (%) for each BoLA-DRB3 allele.

Table 2

Fisher’s exact test based association analysis of BoLA-DRB3 alleles in asymptomatic and lymphoma cows.

BoLA-DRB3 AlleleAsymptomatic (250 Cattle)Lymphoma (221 Cattle)ORp-Valuep-Value Rank (I)BH Value (I/Allele Number)*0.05Susceptibility
*001:01 70701.1560.463 -
*002:01 13131.1351.000 -
*006:01 331.1321.000 -
*007:01 1330.2560.02460.009-
*009:02 1940.2310.00550.008R
*010:01 64290.4780.00120.003R
*011:01 111610.5610.00120.003R
*012:01 22492.7090.00010.002S
*014:01:01 44230.5690.042 -
*015:01 821091.6690.00240.006S
*016:01 14171.3890.578 -
*018:01 383.0540.127 -
*027:03 31311.1410.693 -

The Benjamini–Hochberg (BH) procedure was performed to adjust the false positive rate. Alleles with a p-value < BH value were defined as susceptibility (S) with an odds ratio (OR) > 1 and as resistance (R) with an OR < 1. BH value = (p-value rank/total allele number) × 0.05.

To exclude the effect from other potential factors that might associate with lymphoma development such as cow origin and age, we then applied multivariable logistic regression to adjust for the effect of these potential factors. Our calculation indicates that age showed a significant association with disease susceptibility (p = 6.56 × 10−6). However, no significant difference was observed between location and lymphoma susceptibility (p = 0.182). Therefore, we performed the logistic regression analysis adjusted by age in the only association study of lymphoma. After studying the association between each BoLA-DRB3 allele and lymphoma susceptibility, we conducted a stepwise conditional analysis with respect to the top-associated BoLA-DRB3 alleles (Table S4). In Table 3, a conditional analysis of DRB3*011:01 revealed an independent association with DRB3*009:02 and DRB3*010:01. A subsequent conditional analysis regarding DRB3*009:02 and DRB3*011:01 revealed an independent association with DRB3*010:01 and DRB3*014:01:01. Next, the subsequent conditional analysis of DRB3*009:02, DRB3*010:01, and DRB3*011:01 revealed an independent association with DRB3*014:01:01. After conditioning DRB3*009:02, DRB3*010:01, DRB3*011:01, and DRB3*014:01:01, no significant association locus was observed. We then conducted a multivariate regression analysis incorporating the four associated BoLA-DRB3 alleles (DRB3*009:02, DRB3*010:01, DRB3*011:01, and DRB3*014:01:01). We identified that all were independently associated with lymphoma resistance (Table 3).
Table 3

Logistic regression analysis-based association study of BoLA-DRB3 alleles in asymptomatic and lymphoma cows after adjustments for age.

BoLA-DRB3 AlleleUnivariateMultivariate
p-ValueORL95U95p-ValueORL95 1U95 2
*009:02 0.0020.100.020.434.27 × 10−40.070.010.30
*010:01 0.0080.520.320.847.38 × 10−40.430.0260.70
*011:01 9.91 × 10−40.530.360.775.77 × 10−60.400.270.59
*014:01:01 0.0260.530.300.937.82 × 10−40.360.200.66

1 L95, lower 95% confidence interval. 2 U95, upper 95% confidence interval.

For the genotype association study, genotypes with frequencies > 1% are shown in Figure 3 (complete genotype frequencies are summarized in Table S5). However, no genotypes reached statistical significance in terms of their association with lymphoma development after BH correction to adjust the false discovery rate (Table 4).
Figure 3

Comparison of BoLA-DRB3 genotype frequency between asymptomatic and lymphoma cows. Genotype frequency of 250 asymptomatic (■) and 221 lymphoma (□) cows was calculated for each BoLA-DRB3 genotype (Table S4); a total of 31 out of 94 genotypes with frequency > 1% are shown. The X-axis and Y-axis show the genotype name and frequency (%) for each BoLA-DRB3 genotype, respectively.

Table 4

Fisher’s exact test based association analysis of BoLA-DRB3 genotypes in asymptomatic and lymphoma cows.

BoLA-DRB3GenotypeAsymptomatic(212 Cattle)Lymphoma(221 Cattle)ORp-Valuep-ValueRank (I)BH Value(I/Genotype Number)*0.05Susceptibility
*001:01/*001:01 3145.5680.005 -
*001:01/*007:01 420.5620.689 -
*001:01/*010:01 840.5580.393 -
*001:01/*011:01 2460.2630.00210.0005-
*001:01/*012:01 351.9060.483 -
*001:01/*014:01:01 710.1580.393 -
*001:01/*015:01 9101.2690.645 -
*001:01/* 016:01 320.7521.000 -
*001:01/*018:01 122.2740.603 -
*001:01/*027:03 472.0120.362 -
*002:01/*015:01 144.5900.191 -
*005:03/*016:01 02-0.220 -
*007:01/*011:01 6000.057 -
*009:02/*010:01 80-0.008 -
*010:01/*010:01 720.3170.183 -
*010:01/*011:01 1470.5510.264 -
*010:01/*012:01 420.5620.689 -
*010:01/*014:01:01 530.6740.728 -
*010:01/*015:01 830.4160.231 -
*011:01/*011:01 970.8761.000 -
*011:01/*012:01 451.4240.740 -
*011:01/*014:01:01 1230.2730.037 -
*011:01/*015:01 30140.4960.039 -
*011:01/*027:03 1250.4590.215 -
*012:01/*012:01 08-0.00210.0005-
*012:01/*014:01:01 320.7521.000 -
*012:01/*015:01 5153.5680.011 -
*014:01:01/*015:01 410.2800.377 -
*015:01/*015:01 7183.0780.013 -
*015:01/*016:01 231.7060.669 -
*015:01/*027:03 2105.8770.016 -

The Benjamini–Hochberg (BH) procedure was performed, to adjust the false positive rate. Genotypes with a p-value < BH value were defined as susceptibility (S) with an odds ratio (OR) > 1 and as resistance (R) with an OR < 1. BH value = (p-value rank / total allele number) × 0.05.

3.3. Association Study of BoLA-DRB3 with PVL

Subsequently, to determine the association between BoLA-DRB3 and BLV PVL, we selected an additional 361 asymptomatic cows, in addition to the original 250 asymptomatic cows (used in Figure 1, Figure 2 and Figure 3). A total of 611 asymptomatic cows were then divided into the HPVL group (n = 294; Table S6) and LPVL group (n = 317; Table S6). The frequencies of BoLA-DRB3 alleles from LPVL cows and HPVL cows were calculated by Fisher’s exact test, and p-values and ORs were estimated for each allele (Table S7). The analysis of allele frequencies (Figure 4) and association (Table 5) established DRB3*002:01 (OR = 0.15), *009:02 (OR = 0.07), and *014:01:01 (OR = 0.61) as BLV PVL resistance alleles, consistent with previous findings [20]. In addition, DRB3*012:01 (OR = 3.84) was identified as a susceptibility allele.
Figure 4

Comparison of BoLA-DRB3 allele frequencies between LPVL and HPVL cows. BoLA-DRB3 allele frequencies in LPVL and HPVL cows. The 611 asymptomatic cows comprised 317 LPVL and 294 HPVL individuals. The allele frequencies were calculated in LPVL (■) and HPVL cows (□) for each BoLA-DRB3 allele (Table S6). Total of 12 out of 26 alleles with frequency > 1% are shown.

Table 5

Fisher’s exact test based association analysis of BoLA-DRB3 alleles in low PVL and high PVL cows.

BoLA-DRB3AlleleLow PVL(317 Cattle)High PVL(294 Cattle)ORp-Valuep-ValueRank (I)BH Value(I/Genotype Number)*0.05Susceptibility
*001:01 100991.86810.6046 -
*002:01 2930.1458< 0.000110.0019R
*007:01 11121.57440.8322 -
*009:02 4120.0685< 0.000110.0019R
*010:01 62661.79890.4262 -
*011:01 1331392.29670.1933 -
*012:01 28643.8383< 0.000110.0019S
*014:01:01 59240.60680.000440.0077R
*015:01 1021252.54630.022450.0096-
*016:01 12101.19620.8314 -
*018:01 179.9680.0319 -
*027:03 39291.12490.369 -

Benjamini–Hochberg (BH) procedure was performed to adjust the false positive rate. Alleles with p-value < BH value were defined as susceptibility (S) with odds ratio (OR) > 1, and as resistance (R) with OR < 1. BH value = (p-value rank / total allele number) × 0.05.

Next, to exclude the bias that might occur in Fisher’s exact test, we assessed the association between PVL and other potential factors, including age and the cows’ birth location. However, no association between age (p = 0.170)/location (p = 0.991) and PVL was observed. After studying the association between each BoLA-DRB3 allele and PVL, we conducted stepwise conditional analysis, with respect to the top-associated BoLA-DRB3 alleles (Table S8). In Table 6, a conditional analysis of DRB3*009:02 revealed an independent association with DRB3*002:01, DRB3*012:01, and DRB3*014:01:01. A subsequent conditional analysis regarding DRB3*009:02 and DRB3*014:01:01 revealed an independent association with DRB3*002:01 and DRB3*012:01. Next, a conditional analysis of DRB3*009:02, DRB3*012:01, and DRB3*014:01:01 revealed an independent association with DRB3*002:01. After conditioning DRB3*002:01, DRB3*009:02, DRB3*012:01, and DRB3*014:01:01, no significant association locus was observed. We then conducted a multivariate regression analysis, incorporating the four associated BoLA-DRB3 alleles (DRB3*002:01, DRB3*009:02, DRB3*012:01, and DRB3*014:01:01). We identified that DRB3*002:01, DRB3*009:02, and DRB3*014:01:01 are resistance alleles and DRB3*012:01 is a susceptibility allele independently associated with PVL (Table 6).
Table 6

Logistic regression analysis based association study of BoLA-DRB3 alleles in low PVL and high PVL cows after adjustment of age.

BoLA-DRB3AlleleUnivariateMultivariate
p-ValueORL95U95p-ValueORL95U95
*002:01 6.28 × 10−40.130.040.415.19 × 10−40.120.040.40
*009:02 3.29 × 10−50.050.010.201.42 × 10−50.040.010.17
*012:01 4.00 × 10−52.651.664.223.20 × 10−42.511.524.15
*014:01:01 2.40 × 10−40.390.230.642.10 × 10−50.310.180.53

L95, lower 95% confidence interval. U95, upper 95% confidence interval.

For genotype association study (Table S9), the genotypes with frequency > 1% are shown in Figure 5. The Fisher’s exact test of genotype association (Table 7) indicated that DRB3*009:02/*015:01 (OR = 0) was determined as the resistance genotype. In contrast, DRB3*011:01/*012:01 (OR = 6.83), was determined as the susceptibility genotype.
Figure 5

Comparison of BoLA-DRB3 genotype frequencies between HPVL and LPVL cows. The genotype frequencies of 317 LPVL (■) and 294 HPVL cows (□) were calculated for each BoLA-DRB3 genotype (Table S9); a total of 36 out of 92 genotypes with frequencies > 1% are shown. The X-axis and Y-axis show the genotype name and frequency (%) for each BoLA-DRB3 genotype, respectively.

Table 7

Fisher’s exact test based association analysis of BoLA-DRB3 genotypes in low PVL and high PVL cows.

BoLA-DRB3GenotypeLow PVL(317 Cattle)High PVL(294 Cattle)ORp-Valuep-ValueRank (I)BH Value(I/Genotype Number)*0.05Susceptibility
*001:01/*001:01 4133.62010.0245 -
*001:01/*002:01 1000.00000.001930.0016-
*001:01/*009:02 500.00000.0624 -
*001:01/*010:01 781.23880.7958 -
*001:01/*011:01 27200.78400.4511 -
*001:01/*012:01 591.97050.2824 -
*001:01/*014:01:01 830.39820.2260 -
*001:01/*015:01 15201.46960.2990 -
*001:01/*027:03 960.71300.6067 -
*002:01/*011:01 410.26710.3747 -
*007:01/*011:01 351.81080.4908 -
*007:01/*012:01 133.25770.3559 -
*009:02/*010:01 700.00000.0156 -
*009:02/*012:01 500.00000.0624 -
*009:02/*015:01 1300.00000.000210.0005R
*010:01/*010:01 750.76620.7741 -
*010:01/*011:01 9243.04200.0039 -
*010:01/*012:01 341.44370.7160 -
*010:01/*014:01:01 410.26710.3747 -
*010:01/*015:01 8101.36000.6341 -
*010:01/*016:01 320.71691.0000 -
*010:01/*027:03 331.07901.0000 -
*011:01/*011:01 17110.68590.4393 -
*011:01/*012:01 3186.82610.000520.0011S
*011:01/*014:01:01 1470.52790.1883 -
*011:01/*015:01 19321.91560.0396 -
*011:01/*027:03 1260.52950.2370 -
*012:01/*012:01 04-0.0530 -
*012:01/*014:01:01 620.35500.2886 -
*012:01/*015:01 2126.70210.0053 -
*012:01/*027:03 242.17240.4351 -
*014:01:01/*015:01 1860.34610.0223 -
*014:01:01/*027:03 320.71691.0000 -
*015:01/*015:01 6193.58120.0067 -
*015:01/*016:01 320.71691.0000 -
*015:01/*027:03 341.44370.7160 -

The Benjamini–Hochberg (BH) procedure was performed to adjust the false positive rate. Alleles with a p-value < BH value were defined as susceptibility (S) with an odds ratio (OR) > 1 and as resistance (R), with an OR < 1. BH value = (p-value rank / total allele number) × 0.05.

3.4. Differential Susceptibility of BoLA-DRB3 Polymorphisms to Lymphoma and PVL

We compared the effect of BoLA-DRB3 on cow susceptibility to lymphoma and PVL, based on the multivariable logistic regression analysis in Figure 2 and Figure 4. Several different types of BoLA-DRB3 alleles were found to be associated with BLV-induced lymphoma and BLV PVL (Figure 6). There were two lymphoma resistance alleles, DRB3*010:01, and DRB3*011:01, but no susceptibility alleles were identified. In addition, one allele associated with PVL resistance, DRB3*002:01, and one PVL susceptibility allele, DRB3*012:01, were found. Two resistance alleles, DRB3*009:02 and DRB3*014:01:01, were commonly identified in lymphoma and BLV PVL.
Figure 6

Summary of the differences in BoLA-DRB3 allele-associated proviral load (PVL) and lymphoma susceptibility, based on the logistic regression association study results. R, resistance; S, susceptibility.

3.5. BoLA-DRB3 Polymorphisms Are Associated with anti-BLV Antibody Production Levels

Finally, we tried to link the potential biological functions with BoLA-DRB3 polymorphisms. Previously, it has been demonstrated that PVL resistance and susceptibility alleles are associated with anti-BLV antibody production levels [34]. Here, we hypothesized that only PVL-associated alleles, but not lymphoma-associated alleles, would be related to viral antigen-induced immune responses. To test this, we compared the anti-BLV antibody (anti-gp51) production level between the cows with the PVL susceptibility allele (DRB3*012:01), PVL resistance allele (DRB3*002:01), PVL/lymphoma resistance allele (DRB3*009:02), and lymphoma-specific resistance allele (DRB3*011:01), as shown in the summary in Figure 6. Two-fold serially-diluted plasma samples were tested by ELISA and the OD value in each BoLA-DRB3 group was compared at the dilution of 1:2048. Cows with the PVL resistance allele (PVL resistance group and PVL/lymphoma resistance group) had significantly lower anti-gp51 production levels compared to those in cows carrying the PVL susceptibility allele (p = 0.006 and p = 0.012 respectively; Figure 7). However, cows with the lymphoma specific resistance allele did not have explicitly and significantly different levels of anti-gp51, compared to those in animals with the PVL susceptibility allele (p = 0.474), suggesting that the lymphoma specific associated allele has a lesser effect on anti-gp51 production than the PVL associated allele.
Figure 7

Differential anti-BLV antibody production level in cows with proviral load (PVL) susceptibility, PVL resistance, PVL/lymphoma resistance, and lymphoma-resistance BoLA-DRB3 allele. The PVL susceptibility group consisted of cows with the PVL susceptibility allele DRB3*012:01 (n = 20). The PVL resistance group consisted of cows with the PVL resistance allele DRB3*002:01 (n = 6). The PVL/lymphoma resistance group consisted of cows with the PVL resistance allele DRB3*009:02 (n = 20). The lymphoma resistance group consisted of the lymphoma resistance allele *011:01 (n = 20). The anti-BLV gp51 antibody was measured in plasma at a 211 dilution level. Optical Density (OD) value data represent the mean ± SD. Statistical comparisons were performed by one-way ANOVA. *, p < 0.05. **, p < 0.01. ns, not significant.

4. Discussion

In the present study, by using both Fisher’s exact test and multivariable logistic regression analysis, we showed for the first time that the susceptibility to BLV-induced lymphoma and PVL is affected by different BoLA-DRB3 polymorphisms. For example, two BoLA-DRB3 alleles, DRB3*010:01, and DRB3*011:01, were found to be associated with resistance to lymphoma but not to PVL. In addition, DRB3*002:01 was specifically associated with PVL resistance. In contrast, we found that DRB3*009:02 was common between lymphoma and PVL resistance, in line with the reciprocal association between PVL and lymphoma development. Thus, we might conclude that host polymorphisms at the BoLA-DRB3 locus are an important factor in both PVL and lymphoma development; interestingly, the PVL-associated BoLA-DRB3 allele did not show a major correlation with the lymphoma-associated BoLA-DRB3 allele. The potential reason for the differential susceptibility to PVL and Lymphoma might be the differential immune response, which depends on BoLA-DRB3 polymorphisms, as we found that the level of anti-BLV antibody is related to the PVL-associated allele but not the lymphoma-associated allele, suggesting that lymphoma specific-associated alleles have a lesser effect on anti-BLV antibody production than PVL-associated alleles. Some discrepancies were observed between the association based on Fisher’s exact test and multivariable logistic regression analysis. For example, DRB3*015:01 was indicated as a lymphoma susceptibility allele by Fisher’s exact test, but not by multivariable logistic regression analysis. The inconsistencies can also be found in DRB3*012:01 and DRB3*014:01:01. This is a common problem between these two statistical methods, as Fisher’s exact test includes all factors, such as environmental and genetically factors, that together influence BoLA-DRB3 polymorphisms. In contrast, multivariable logistic regression can adjust for the effect of other associated factors, such as age, for the lymphoma association study. Therefore, further experiments for allele functional confirmation are needed. It is not clear how most BLV-infected cattle do not develop bovine leukosis. The following findings in our study may help solve this issue: (i) In asymptomatic cows, two of the major BoLA-DRB3 alleles, DRB3*011:01 (22%) and DRB3*010:01 (12%), were significantly associated with lymphoma resistance, but were unrelated to PVL. This may explain why some HPVL cows remained asymptomatic. (ii) Susceptibility alleles specifically associated with lymphoma were absent in Japanese Holstein cows, suggesting that malignant transformation requires other factors, besides BoLA-DRB3 polymorphism. For instance, the deregulation of lymphocyte homeostasis is known to lead to leukemia [35]. Provirus integration close to cancer-driver sites and transcriptionally active regions may affect host gene expression [23,36,37]. The viral accessory proteins Tax and G4 also play a crucial role in cell transformation [38]. Besides, p53 mutation [39,40] and tumor necrosis factor-α polymorphisms [41] are also related to lymphoma development. The major function of MHC class II molecules is to present antigens for T cells to activate the adaptive immune response. It is possible that PVL-specific BoLA-DRB3 and lymphoma-specific BoLA-DRB3 recognize different antigens and thus the subsequent immune response targeting the virus or tumor cells, respectively. To link BoLA-DRB3 polymorphisms with their biological functions, we tested the anti-BLV gp51 antibody level in cows with the PVL-associated BoLA-DRB3 allele and lymphoma-associated BoLA-DRB3 allele. Interestingly, significantly different anti-gp51 levels were found between cows with PVL resistance and PVL susceptibility alleles. However, no significant difference was found in cows carrying lymphoma-specific resistance alleles compared to those in cows carrying PVL susceptibility alleles. This result is in line with the hypothesis that proteins encoded by PVL-associated and lymphoma-associated BoLA-DRB3 alleles recognize different antigens and thus trigger different subsequent immune responses. Similar to that in a previous study, we found that cows with PVL resistance alleles exhibit significantly lower anti-gp51 levels than cows with PVL susceptibility alleles [34]. This is probably because we measured anti-gp51 levels in steady state virus infections, and thus, the antibody concentration might change and correlate with the viral titer in cows. As a result, in PVL resistance cows, which are associated with low viral expression levels, a low anti-BLV antibody level would be detected. In addition to humoral immunity, whether BoLA-DRB3 polymorphisms are associated with effects on cytotoxic T lymphocytes needs further study. In the PVL association study, DRB3*015:01 has been reported as a PVL susceptibility allele in our and other studies [19,34]. However, we found only one PVL susceptibility allele, DRB3*012:01, in the current investigation. This difference might be due to the sample collection bias and also the statistical analysis method. For the lymphoma association study, it has been reported that the BoLA-DRB3*018:02, DRB3*032:02, and DRB3*009:01 alleles are associated with the susceptibility to BLV-induced lymphoma, whereas DRB3*001:01 and DRB3*011:01 are involved in lymphoma resistance in Iranian Holstein cows [17]. In the present study, DRB3*011:01 was confirmed to be a resistance allele. The other identified alleles were different from those previously reported, suggesting that regional genetic variations may exist. Indeed, ethnicity-related differences in the frequency of human MHC alleles have been observed [42,43]. Furthermore, allelic diversity in the BoLA locus between cattle breeds has been previously demonstrated [44,45,46,47]. This variability is strongly influenced by selective pressures such as exposure to infectious diseases and breed origin. Therefore, the association between the BoLA-DRB3 locus and the resistance or susceptibility to BLV-induced lymphoma, as well as the regulation of PVL, should be further explored in different countries and in distinct cow breeds. In conclusion, we have demonstrated for the first time that BLV-induced lymphoma and PVL are associated with different BoLA-DRB3 alleles in Holstein cows in Japan. Although BLV infects cattle worldwide, effective treatments and vaccines are not available. Consequently, breed selection based on BoLA-DRB3 polymorphism is a promising strategy to reduce the burden of BLV-induced lymphoma. Contrarily, the sporadic inconsistency between PVL and terminal diseases might be a common phenomenon, due to host genetic polymorphisms during different infectious viral diseases. Indeed, partial inconsistency between PVL and the related symptoms was also observed in HTLV-1-infected patients [48]. As BLV is closely related to HTLV-1, the consistency between the susceptibility of host genetic polymorphisms with PVL and HTLV-1-related symptoms is worth confirming.
  44 in total

1.  HLA class I allele distributions in six Pacific/Asian populations: evidence of selection at the HLA-A locus.

Authors:  T L Bugawan; S J Mack; M Stoneking; M Saha; H P Beck; H A Erlich
Journal:  Tissue Antigens       Date:  1999-04

2.  BLV-CoCoMo-qPCR-2: improvements to the BLV-CoCoMo-qPCR assay for bovine leukemia virus by reducing primer degeneracy and constructing an optimal standard curve.

Authors:  Shin-nosuke Takeshima; Yuri Kitamura-Muramatsu; Yuan Yuan; Meripet Polat; Susumu Saito; Yoko Aida
Journal:  Arch Virol       Date:  2015-03-04       Impact factor: 2.574

3.  Monitoring the HTLV-1 proviral load in the peripheral blood of asymptomatic carriers and patients with HTLV-associated myelopathy/tropical spastic paraparesis from a Brazilian cohort: ROC curve analysis to establish the threshold for risk disease.

Authors:  Marina dos Santos Brito Silva Furtado; Rafaela Gomes Andrade; Luiz Cláudio Ferreira Romanelli; Maisa Aparecida Ribeiro; João Gabriel Ribas; Elídio Barbosa Torres; Edel Figueiredo Barbosa-Stancioli; Anna Bárbara de Freitas Carneiro Proietti; Marina Lobato Martins
Journal:  J Med Virol       Date:  2012-04       Impact factor: 2.327

4.  The diversity of bovine MHC class II DRB3 and DQA1 alleles in different herds of Japanese Black and Holstein cattle in Japan.

Authors:  Taku Miyasaka; Shin-nosuke Takeshima; Yuki Matsumoto; Naohiko Kobayashi; Tamako Matsuhashi; Yoshiyuki Miyazaki; Yoshihiro Tanabe; Kazuki Ishibashi; Hiroshi Sentsui; Yoko Aida
Journal:  Gene       Date:  2010-10-19       Impact factor: 3.688

5.  HLA-DRB1 and HLA-DQB1 polymorphisms in Pacific Islands populations.

Authors:  Z M Velickovic; B Delahunt; J M Carter
Journal:  Tissue Antigens       Date:  2002-05

6.  Risk factors associated with increased bovine leukemia virus proviral load in infected cattle in Japan from 2012 to 2014.

Authors:  Ayumu Ohno; Shin-nosuke Takeshima; Yuki Matsumoto; Yoko Aida
Journal:  Virus Res       Date:  2015-08-29       Impact factor: 3.303

7.  Distribution and origin of bovine major histocompatibility complex class II DQA1 genes in Japan.

Authors:  S Takeshima; S Chen; M Miki; M Kado; Y Aida
Journal:  Tissue Antigens       Date:  2008-09

8.  Early events following bovine leukaemia virus infection in calves with different alleles of the major histocompatibility complex  DRB3 gene.

Authors:  Agustina Forletti; Claudia María Lützelschwab; Rosana Cepeda; Eduardo N Esteban; Silvina Elena Gutiérrez
Journal:  Vet Res       Date:  2020-01-13       Impact factor: 3.683

Review 9.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

Review 10.  Mechanisms of pathogenesis induced by bovine leukemia virus as a model for human T-cell leukemia virus.

Authors:  Yoko Aida; Hironobu Murakami; Masahiko Takahashi; Shin-Nosuke Takeshima
Journal:  Front Microbiol       Date:  2013-11-08       Impact factor: 5.640

View more
  11 in total

1.  Comprehensive Comparison of Novel Bovine Leukemia Virus (BLV) Integration Sites between B-Cell Lymphoma Lines BLSC-KU1 and BLSC-KU17 Using the Viral DNA Capture High-Throughput Sequencing Method.

Authors:  Meripet Polat Yamanaka; Susumu Saito; Kazuyoshi Hosomichi; Yoko Aida
Journal:  Viruses       Date:  2022-05-07       Impact factor: 5.818

2.  Risk Assessment of Bovine Major Histocompatibility Complex Class II DRB3 Alleles for Perinatal Transmission of Bovine Leukemia Virus.

Authors:  Liushiqi Borjigin; Chieh-Wen Lo; Lanlan Bai; Rania Hamada; Hirotaka Sato; Shuji Yoneyama; Anna Yasui; Sohei Yasuda; Risa Yamanaka; Munehito Mimura; Michihito Inokuma; Yasuo Shinozaki; Naoko Tanaka; Shin-Nosuke Takeshima; Yoko Aida
Journal:  Pathogens       Date:  2021-04-22

3.  Analysis of the bone morphogenetic protein 6 gene promoter region in young beef cattle affected by enzootic bovine leukosis.

Authors:  Masaki Maezawa; Ken-Ichi Watanabe; Kotaro Matsumoto; Yoshiyasu Kobayashi; Haruko Ogawa; Hisashi Inokuma
Journal:  J Vet Med Sci       Date:  2021-04-09       Impact factor: 1.267

4.  PRMT5 Is Required for Bovine Leukemia Virus Infection In Vivo and Regulates BLV Gene Expression, Syncytium Formation, and Glycosylation In Vitro.

Authors:  Wlaa Assi; Tomoya Hirose; Satoshi Wada; Ryosuke Matsuura; Shin-Nosuke Takeshima; Yoko Aida
Journal:  Viruses       Date:  2020-06-16       Impact factor: 5.048

5.  BoLA-DRB3 Polymorphism Controls Proviral Load and Infectivity of Bovine Leukemia Virus (BLV) in Milk.

Authors:  Ayumi Nakatsuchi; Sonoko Watanuki; Liushiqi Borjigin; Hirotaka Sato; Lanlan Bai; Ryosuke Matsuura; Maho Kuroda; Hironobu Murakami; Reiichiro Sato; Sakurako Asaji; Asako Ando; Yasunobu Matsumoto; Shin-Nosuke Takeshima; Yoko Aida
Journal:  Pathogens       Date:  2022-02-05

6.  Molecular Characterization of Bovine Leukemia Virus with the Evidence of a New Genotype Circulating in Cattle from Kazakhstan.

Authors:  Akhmetzhan Sultanov; Marzena Rola-Łuszczak; Saltanat Mamanova; Anna Ryło; Zbigniew Osiński; Meruyert A Saduakassova; Elvira Bashenova; Jacek Kuźmak
Journal:  Pathogens       Date:  2022-01-28

7.  Genomic evaluation of hybridization in historic and modern North American Bison (Bison bison).

Authors:  Sam Stroupe; David Forgacs; Andrew Harris; James N Derr; Brian W Davis
Journal:  Sci Rep       Date:  2022-04-16       Impact factor: 4.996

8.  Relationship between Allelic Heterozygosity in BoLA-DRB3 and Proviral Loads in Bovine Leukemia Virus-Infected Cattle.

Authors:  Hala El Daous; Shuya Mitoma; Eslam Elhanafy; Huyen Thi Nguyen; Ngan Thi Mai; Kosuke Notsu; Chiho Kaneko; Junzo Norimine; Satoshi Sekiguchi
Journal:  Animals (Basel)       Date:  2021-03-01       Impact factor: 2.752

9.  Detection and molecular characterization of bovine leukemia virus in beef cattle presented for slaughter in Egypt.

Authors:  Samy Metwally; Rania Hamada; Alsagher O Ali; Hassan Y A H Mahmoud; Nabil M Baker; Adel E A Mohamed; Satoshi Wada; Yasunobu Matsumoto; Yoko Aida
Journal:  J Vet Med Sci       Date:  2020-10-20       Impact factor: 1.267

10.  Phenotypic Selection of Dairy Cattle Infected with Bovine Leukemia Virus Demonstrates Immunogenetic Resilience through NGS-Based Genotyping of BoLA MHC Class II Genes.

Authors:  Chaelynne E Lohr; Kelly R B Sporer; Kelsey A Brigham; Laura A Pavliscak; Matelyn M Mason; Andrew Borgman; Vickie J Ruggiero; Tasia M Taxis; Paul C Bartlett; Casey J Droscha
Journal:  Pathogens       Date:  2022-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.